Olga C. Aroniadis

Olga C. Aroniadis

Auto-generated profile, based on publicly available information

Olga C. Aroniadis

Division of Gastroenterology, Department of Internal Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook University Hospital, Stony Brook, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
PFPaul Feuerstadt
Paul Feuerstadt
OAOlga C. Aroniadis
Olga C. Aroniadis
FSFelicia L. Svedlund
Felicia L. Svedlund
MGMariana Garcia
Mariana Garcia
LSLaura Stong
Laura Stong
SKSahil Khanna
Sahil Khanna
Introduction Clinical trials have demonstrated the efficacy of FMT for reduction in CDI recurrences (rCDI), but this treatment and its reporting in the literature has significant heterogeneity. Recent publications (e.g., Ramai et al. in Dig Dis Sci 2020. https://doi.org/10.1007/s10620-020-06185-7) present the clinical outcomes for different FMT methodologies. However, to understand, compare, and contextualize outcomes, this heterogeneity in methods and reporting must be understood. Methods We performed a literature review of randomized controlled trials (RCTs) of FMT for rCDI to evaluate heterogeneity among trials. A methodical search between January 2010 and May 2019 of Medline, Embase, and Cochrane was conducted for studies investigating FMT in adults with rCDI. RCTs were evaluated for a variety of methodological and reporting criteria. Results Eight RCTs were identified, wherein 14 different FMT preparations were considered (each with distinct protocols for processing, storage, administration, and dosing). Sample sizes were generally small, with only two studies performing FMT in more than 100 patients. Three studies used non-FMT controls (vancomycin), while the remaining compared FMT with differing routes of administration or formulations. Across the identified studies, there was no standardized manner for reporting the timing of the FMT procedure. All studies tracked adverse events; however, follow-up periods were limited. Conclusions Considerable variability exists among RCTs, with marked differences in study design, control groups, and outcome assessment. Lack of a standard-of-care control in many trials may impact reproducibility of FMT trial outcomes in patients with rCDI. Widespread use of FMT for rCDI is still investigational; therefore, these foundational studies provide opportunities to optimize future trials.

1 May 2013 in Gastroenterology
Verified
Journal Article
Closed access
OAOlga C. Aroniadis
Olga C. Aroniadis
LBLawrence J. Brandt
Lawrence J. Brandt
AGAdam Greenberg
Adam Greenberg
TBThomas Julius Borody
Thomas Julius Borody
CKColleen Kelly
Colleen Kelly
LNLeila Neshatian
Leila Neshatian

9 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BEB. Joseph Elmunzer
B. Joseph Elmunzer
RSRebecca L. Spitzer
Rebecca L. Spitzer
LFLydia D. Foster
Lydia D. Foster
AMAmbreen A. Merchant
Ambreen A. Merchant
EHEric F. Howard
Eric F. Howard
HNHaley Nitchie
Haley Nitchie
Background: The prevalence and significance of digestive manifestations in COVID-19 remain uncertain. Methods: Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. Results: A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death. Conclusions: Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course

9 November 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
OAOlga C. Aroniadis
Olga C. Aroniadis
XWXianling Wang
Xianling Wang
TGTang Gong
Tang Gong
NFNauzer Forbes
Nauzer Forbes
JYJeong Yun Yang
Jeong Yun Yang
DYDhiraj Yadav
Dhiraj Yadav

27 October 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
FAFeyzullah Aksan
Feyzullah Aksan
AAAlan Abboud
Alan Abboud
Lokman H. TanriverdiLokman H. Tanriverdi
Lokman H. Tanriverdi
OAOlga C. Aroniadis
Olga C. Aroniadis
FMFarah Monzur
Farah Monzur

10 August 2025 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
OAOlga C. Aroniadis
Olga C. Aroniadis
BGBeth Guthmueller
Beth Guthmueller
KDKaitlin Dehlin
Kaitlin Dehlin
SSShivam Srivastava
Shivam Srivastava
PFPaul Feuerstadt
Paul Feuerstadt
HWHorst C. Weber
Horst C. Weber
The safety and efficacy of microbiota-based products in patients with irritable bowel syndrome (IBS) and recurrent Clostridioides difficile infection (rCDI) has not been studied. Fecal microbiota, live-jslm (RBL; REBYOTA®) is an FDA-approved, single-dose, microbiota-based product to prevent rCDI in adults following standard-of-care (SOC) antibiotic treatment. This was an exploratory subgroup analysis of PUNCH CD3-OLS, a phase 3, open-label, prospective study conducted in the United States (US) and Canada, to evaluate the safety and efficacy of RBL in participants with documented rCDI and concurrent IBS. Participants aged ≥ 18 years with a diagnosis of rCDI and who completed SOC antibiotic treatment were enrolled in this study. The primary endpoint of PUNCH CD3-OLS was the number of participants with RBL- or administration-related treatment-emergent adverse events (TEAEs). Secondary endpoints included treatment success at 8 weeks and sustained clinical response at 6 months. In this subgroup analysis, ongoing IBS was confirmed based on medical record documentation at the time of RBL administration. Among the 697 RBL recipients, 90 had comorbid IBS. After RBL administration, 52 participants with IBS (57.8%) and 278 participants without IBS (45.8%) experienced TEAEs through 8 weeks. Most TEAEs were mild (22.2% with IBS, 20.1% without IBS) or moderate (26.7% with IBS, 18.8% without IBS). Serious TEAEs were reported by 1 participant with IBS (pneumonia reported to be unrelated to RBL) and 26 participants without IBS [most of which were related to preexisting conditions (3.1%)]. Among all participants, 68.9% with IBS and 75.6% without IBS had absence of CDI diarrhea through 8 weeks after RBL administration. Of the participants with treatment success, 82.3% with IBS and 92.2% without IBS had sustained clinical response through 6 months. RBL is a safe and efficacious option to prevent CDI recurrence in patients with concurrent IBS. ClinicalTrials.gov identifier, NCT03931941.